Calixa Therapeutics Announces Initiation of Phase 2 Clinical Trial of Its Antibiotic,...

Calixa Therapeutics Announces Initiation of Phase 2 Clinical Trial of Its
Antibiotic, CXA-101, in Patients with Complicated Urinary Tract Infections

SAN DIEGO, June 30 /PRNewswire/ -- Calixa Therapeutics Inc. today announced
the initiation of a Phase 2 clinical trial of CXA-101 in patients with
complicated urinary tract infections. CXA-101 is a new broad-spectrum,
parenteral cephalosporin antibiotic with excellent in vitro and in vivo
activity against Pseudomonas aeruginosa, including drug resistant isolates.
Calixa is investigating CXA-101 as a potential treatment for serious bacterial
infections in hospitalized patients.

The multi-center, randomized study is anticipated to enroll approximately 120
patients and will compare the efficacy and safety of CXA-101 with the current
standard of therapy. The primary efficacy endpoint for this study is
microbiological outcome at the test-of-cure visit between six to nine days
after the end of therapy.

"The preclinical and Phase 1 results to date are very promising and indicate
that CXA-101 is well tolerated and has broad-spectrum antibacterial coverage,
including potent activity against increasingly resistant gram-negative
pathogens such as Pseudomonas aeruginosa," said Dr. Ian Friedland, chief
medical officer of Calixa. "We are going to present comprehensive preclinical
and Phase 1 data at the 49th Interscience Conference on Antimicrobial Agents
and Chemotherapy in September and other medical conferences. This Phase 2
study will generate important information on the safety and effectiveness of
CXA-101 in complicated urinary tract infections, which are usually caused by
gram-negative pathogens".

Eckard Weber, president and chief executive officer of Calixa and partner at
the venture capital firm Domain Associates, LLC said, "With the continually
increasing incidence of serious and life-threatening infections caused by
resistant gram-negative bacteria and the paucity of new drugs in the pipeline
to counter such resistance, we are working diligently to expedite the
development of CXA-101. We are fully committed to providing patients and
physicians with a much needed option for the treatment of life-threatening
infections caused by gram-negative bacteria."

About Calixa Therapeutics
Calixa Therapeutics Inc. is a biopharmaceutical company committed to the
development and commercialization of novel medicines for the treatment of
infectious diseases. The company's initial focus is on developing novel
antibiotics for use in the hospital setting. Calixa Therapeutics, which is
privately held, is headquartered in San Diego and has operations in the San
Francisco Bay Area. For additional information, please visit:
www.calixainc.com.
Contacts:
Robert Flamm, Ph.D., or David Schull
Russo Partners
(212) 845-4226
robert.flamm@russopartnersllc.com
david.schull@russopartnersllc.com

Eckard Weber, M.D.
Calixa Therapeutics Inc.
(858) 480-2420
stone@domainvc.com

SOURCE Calixa Therapeutics Inc.

Robert Flamm, Ph.D., +1-212-845-4226, robert.flamm@russopartnersllc.com or
David Schull, +1-212-845-4226, david.schull@russopartnersllc.com, both of
Russo Partners; or Eckard Weber, M.D. of Calixa Therapeutics Inc.,
+1-858-480-2420, stone@domainvc.com